Senti Bio Announces Reverse Stock Split
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Senti Bio (Nasdaq: SNTI) will implement a 1-for-33 reverse stock split effective at 5:00 p.m. EDT on November 18, 2026. Split-adjusted trading on The Nasdaq Capital Market begins November 19, 2026. Every 33 issued common shares will become one share, with fractional entitlements rounded up to a whole share.
The action follows an August 27, 2026 Nasdaq notice that the stock had closed below $1.00 for 30 consecutive business days. Senti Bio has until February 23, 2027 to regain compliance, requiring a closing bid of at least $1.00 for at least 10 consecutive business days. The company believes the split will increase its share price and cure the deficiencies. A separate Nasdaq rule provides for immediate suspension after trading at or below $0.10 for ten consecutive trading days; requesting a hearing does not automatically stay that suspension.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- None.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.1-for-33 reverse split addresses minimum-bid deficiencies; Senti Bio believes it will restore compliance.
- Minor point. Forward-looking: it has not happened yet and may not happen.Nasdaq compliance deadline is February 23, 2027, requiring at least $1.00 for 10 consecutive business days.
- Minor point. Forward-looking: it has not happened yet and may not happen.Trading at or below $0.10 for ten consecutive trading days triggers immediate suspension under Nasdaq rules.
Key Figures
- Reverse split ratio
- 1-for-33
- Board-approved reverse stock split
- Minimum bid-price shortfall
- Below $1.00 per share for 30 consecutive business days
- Nasdaq notification cited in the announcement
- Compliance grace period
- 180 calendar days, through February 23, 2027
- Initial period to regain Nasdaq minimum bid-price compliance
- Required bid price
- At least $1.00 per share for a minimum of 10 consecutive business days
- Requirement to regain compliance
- Delisting threshold
- At or below $0.10 for 10 consecutive trading days
- Nasdaq rule described as triggering an immediate delisting determination and trading suspension
- Split effective time
- 5:00 p.m. EDT on November 18, 2026
- Effective time of the reverse stock split
- Split-adjusted trading begins
- November 19, 2026
- Opening of trading on The Nasdaq Capital Market
Key Terms
reverse stock split financial
par value financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Shares expected to begin trading on split-adjusted basis on November 19, 2026
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors has determined to effect a one-for-thirty-three (1-for-33) reverse stock split of Senti Bio’s common stock, par value
The reverse stock split will take effect at 5:00 p.m. EDT on November 18, 2026, and Senti Bio’s common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on November 19, 2026. The CUSIP number of 816944201 will be assigned to Senti Bio’s common stock when the reverse stock split becomes effective.
When the reverse stock split becomes effective, every thirty-three (33) of Senti Bio’s issued shares of common stock will be combined into one issued share of common stock, without any change to the par value per share. This will reduce the number of outstanding shares of common stock from approximately 85,706,263 million shares to approximately 2,597,160 million shares.
No fractional shares will be issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive a fractional share of Common Stock will have such fractional share rounded up to the nearest whole share.
Stockholders with shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the consequence of the reverse stock split reflected in their accounts on or after November 19, 2026. Such beneficial holders may contact their bank, broker, or nominee for more information.
The reverse stock split ratio approved by the Board of Directors is within the previously disclosed range of ratios for a reverse stock split authorized by the stockholders of Senti Bio at the 2026 Annual Meeting of Stockholders of Senti Bio.
As previously announced, on August 27, 2026, the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notified Senti Bio that the bid price for Senti Bio’s common stock had closed below
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. Senti Bio’s wholly-owned pipeline utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio has also preclinically demonstrated the potential breadth Gene Circuits in other modalities, diseases outside of oncology, and continues to advance these capabilities through partnerships with Spark Therapeutics and BlueRock Therapeutics.
Forward-Looking Statements
This press release contains certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended including statements with respect to Senti Bio’s ability to regain compliance with Nasdaq’s continued listing standards and remain listed on Nasdaq or any other major stock exchange and other statements that are forward looking. These forward-looking statements generally are identified by the words “believe,” “could,” “predict,” “continue,” “project,” “expect,” “anticipate,” “future,” “may,” “should,” “will,” “would,” “will be,” “target” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio’s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, the expected timing and effectiveness of the reverse stock split and authorized share reduction; the anticipated trading price of Senti Bio’s common stock following the reverse stock split; and the anticipated impact of the reverse stock split on Senti Bio’s ability to regain and maintain compliance with the Nasdaq minimum bid price requirement. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Senti Bio’s Annual Report on Form 10-K, filed with the SEC on March 27, 2026, Senti Bio’s Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2026, Senti Bio’s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2026, and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio’s assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Availability of Other Information About Senti Biosciences Holdings, Inc.
For more information, please visit the Senti Bio website at https://www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Senti Bio Contacts
Investors: investors@sentibio.com
Media: media@sentibio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Senti Bio's SNTI reverse stock split take effect, and what is the ratio?
Senti Bio's 1-for-33 reverse stock split takes effect at 5:00 p.m. EDT on November 18, 2026. Trading on a split-adjusted basis begins on The Nasdaq Capital Market at the opening of trading on November 19, 2026.